Brief Article on New iwCLL Guidelines - CLL Support
Brief Article on New iwCLL Guidelines
You need to be a member of this community to see this post.
Read more about...
2 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Potential Early Drivers of Disease in Treatment-Naive CLL Identified
This study reinforces others regarding mutations that predict a short time to first treatment....
Determining if you'll never need treatment. It is feasible and safe to stop specialized follow-up of asymptomatic lower risk CLL?
Regular readers will have often heard that around 30% of those diagnosed with CLL never need...
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with CLL
This is an abstract from the Lancet article. There's a fair bit of detail missing regarding the...
Use of MRD Status Following Obinutuzumab/Ibrutinib to Guide Subsequent Intensification of Therapy in CLL
August 6, 2019
In this 2-part, single-arm, open-label, multicenter trial (Clinical Trials.gov...
SF3B1 Mutations
We've had a couple of members mention that they are positive for SF3B1 Mutations so I thought it...
Related Posts
Clinical Trials studying COVID-19 vaccines in CLL: Some have begun/ others are coming!
Zanubrutinib vs. Ibrutinib Patient Power Video by Dr. Jennifer Brown MD PHD- Richter Transformation Survival in CLL Appears Better Among Treatment-Naive
- CLL Society COVID-19 guidelines, & Explaining to Family and Friends Why the CDC Guidelines for Those Vaccinated - Do Not Apply to us
- Expert Perspective on Key Trial Updates in Treatment of CLL: What You Need to Know From ASCO/EHA/ICML 2021
